Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.

Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, immuno-oncology and immunometabolism pathways.

Clinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
    & Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Partner
  • Anticipated
    Milestones

Discovery & Preclinical Projects

Immunooncology & Immunometabolism

  • Program/ Target Name
  • Indication
  • Discovery
    & Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Partner
  • Anticipated
    Milestones
  • A2A/B
    • Solid tumors
  • STING
    • Solid tumors
  • HPK1
    • Solid tumors
  • Novel Targets
    • Solid tumors

Synthetic Lethality

  • SMARCA2/BRM
    • Solid tumors
  • Novel targets
    • Solid tumors

Collaborations

  • Cancer Metabolism
    • Solid Tumors